---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-028876"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:07:47.663301+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo

## Summary
- 43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).
- COAP patients: mean PI-NRS change -1.60 (PIPE-791) vs -1.27 (placebo) in Treatment Period 1.
- CLBP patients: mean PI-NRS change -1.33 (PIPE-791) vs -0.55 (placebo) in Treatment Period 1.
- Exploratory endpoints (≥30% pain reduction, KOOS) further supported positive PI-NRS trends.
- Company plans further evaluation of PIPE-791 for chronic pain; also in Phase 2 PROPEL-IPF (IPF).

## SEC filing metadata
- accession: 0001628280-26-028876
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000162828026028876/0001628280-26-028876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000162828026028876/ctnm-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-028876
- JSON: https://secwatch.observer/filing/0001628280-26-028876.json
- Plain text: https://secwatch.observer/filing/0001628280-26-028876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.